> MorphoSys received FDA breakthrough designation for MOR208 in diffuse large B-cell lymphoma. The FDA awarded the regulatory status to the anti-CD19 antibody on the strength of preliminary data from a phase 2 Revlimid combination trial. Release
> Nicox struck a deal with Re-Vana Therapeutics. The partners will look into combining Nicox’s stand-alone nitric oxide-donors with Re-Vana's biodegradable drug delivery platform. Statement
> UniQure moved to capitalize on the positive response to its pipeline switch up with a stock offering. The gene therapy specialist is offering 5 million shares, positioning it to pull in close to $100 million at its recently-risen stock price. Release
> Ergomed reported top-line data from a phase 2 trial of its coagulant PeproStat. The drug cut time to hemostasis by 1.55 minutes compared to standard of care, a statistically-significant difference that resulted in the trial hitting its primary endpoint. Statement
> Mologen received a $10 million investment from Global Corporate Finance. The money equips Mologen to push ahead with its lefitolimod-focused strategy. Lefitolimod is a clinical-phase TLR9 agonist. Release
> Transgene reported data from a phase 1/1b trial of its hepatitis B immunotherapy TG1050. Two-fifths of participants experienced drug-related adverse events but none were more severe than grade 2. Most of the adverse events were injection site reactions. Statement